is tirzepatide a glp-1 agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data GLP-1/GIP dual agonist tirzepatide normalizes

Clinical studies have demonstrated that GLP-1 receptor agonists, including Ozempic , can support meaningful and sustained weight loss over extended periods

In toxin-induced rodent models of PD (MPTP, 6-OHDA, rotenone, LPS), exendin-4 (142145), liraglutide (146, 147), lixisenatide (146), and semaglutide (57, 148) reduced dopaminergic neuron loss, preserved striatal terminals, and improved motor performance, in association with stabilization of mitochondria, reduced oxidative stress, and reduced inflammation

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

GLP1 receptor agonists (e.g., semaglutide) and dual GLP1 receptor agonists/GIP agonists (e.g., tirzepatide) have been shown to significantly reduce weight in patients with obesity, with and without type 2 diabetes

doi: 10.1016/j.intimp.2020.106715